MadelynElizabethBurkartMD

PubMed

• 1 citations
  A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
  Yazeed Sawalha, Subir Goyal, Jeffrey M Switchenko, Jason T Romancik, Manali Kamdar, I Brian Greenwell, Brian T Hess, Krista M Isaac, Craig A Portell, Alex Mejia Garcia...> ;Blood Advances. 2023 Jul 11
• 11 citations
  Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Cons...
  Talha Badar, Ehab Atallah, Rory Shallis, Antoine N Saliba, Anand Patel, Jan P Bewersdorf, Justin Grenet, Maximilian Stahl, Adam Duvall, Madelyn Burkart, Neil Palmisian...> ;Leukemia. 2023 Apr 1
• 4 citations
  Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
  Narendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, James N Gerson, Stefan K Barta, Max J Gordon, Alexey V Danilov, Natalie S Grover, Stephanie Mathews, Made...> ;Blood Advances. 2023 Jun 13
• 24 citations
  Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
  Talha Badar, Ehab Atallah, Rory M Shallis, Aaron D Goldberg, Anand Patel, Yasmin Abaza, Jan P Bewersdorf, Antoine N Saliba, Guilherme Sacchi De Camargo Correia, Guru M...> ;American Journal of Hematology. 2022 Jul 1
• 31 citations
  Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.
  Abraham, I., Rauscher, G., Patel, A., Pearse, W., Rajakumar, P., Burkart, M., Aleem, A., Dave, A., Bharadwaj, S., Paydary, K., Acevedo-Mendez, M., Goparaju, K., Gomez,...> ;Blood. 2022 Apr 7
• 4 citations
  Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
  Ishan Roy, Madelyn Burkart, Elizabeth Hamilton, Katherine Thorp, Sarah Miyata, Shuo Ma, Barbara Pro, Jane Winter, Leo Gordon, Reem Karmali, Gordon Smilnak> ;British Journal of Haematology. 2022 Apr 1
• 8 citations
  Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
  Madelyn Burkart, Reem Karmali> ;Journal of Personalized Medicine. 2022 Mar 1
• 1 citations
  Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse.
  Timothy S Oh, Madelyn Burkart, Amir Behdad, Hatice Savas, Reem Karmali> ;Case Reports in Hematology. 2022 Jan 1
• 21 citations
  Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy.
  David A. Bond, Jeffrey M. Switchenko, Diego Villa, Kami J. Maddocks, Michael C. Churnetski, Alina S. Gerrie, Subir Goyal, Krithika Shanmugasundaram, Oscar Calzada, Bha...> ;Blood Advances. 2021 Sep 13
• 5 citations
  Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis.
  Christopher D'Angelo, Walter Hanel, Yi Chen, Menggang Yu, David T. Yang, Ling Guo, Reem Karmali, Madelyn Burkart, Colleen Ciccosanti, Kevin A. David, Zachary Risch, Ca...> ;Hematological Oncology. 2021 Aug 4
• 11 citations
  Multi-Center Analysis of Practice Patterns and Outcomes of Younger and Older Patients with Mantle Cell Lymphoma in the Rituximab Era.
  Reem Karmali, Jeffrey M. Switchenko, Subir Goyal, Krithika Shanmugasundaram, Michael C. Churnetski, Bhaskar Kolla, Veronika Bachanova, James N. Gerson, Stefan K. Barta...> ;American Journal of Hematology. 2021 Jul 29
• 17 citations
  HIV-associated Burkitt lymphoma: Outcomes from a US-UK collaborative analysis
  Juan Pablo Alderuccio, Adam J. Olszewski, Andrew M. Evens, Graham P. Collins, Alexey V. Danilov, Mark Bower, Deepa Jagadeesh, Catherine Zhu, Amy Sperling, Seo-Hyun Kim...> ;Blood Advances. 2021 Jul 27
• 3 citations
  Intensive Induction Regimens after Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated with Improved Survival
  Krithika Shanmugasundaram, Subir Goyal, J. Switchenko, Oscar Calzada, Michael C. Churnetski, Bhaskar Kolla, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Max J...> ;European Journal of Haematology. 2021 May 11
• 7 citations
  Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphobl...
  Talha Badar, Aniko Szabo, Mark R. Litzow, Madelyn Burkart, Ilana R. Yurkiewicz, Shira Dinner, Mehrdad Hefazi, Rory M. Shallis, Nikolai A. Podoltsev, Anand Patel, Emily...> ;Bone Marrow Transplantation. 2021 Apr 6
• 12 citations
  Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study
  Adam Zayac, Andrew M. Evens, Alexey V. Danilov, Stephen D. Smith, Deepa Jagadeesh, Lori A. Leslie, Catherine Wei, Seo-Hyun Kim, Seema Naik, Suchitra Sundaram, Nishitha...> ;Haematologica. 2021 Jul 1
• 45 citations
  Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers
  Andrew M. Evens, Alexey V. Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Daniel Rector, Suchitra Sundaram, Nishitha Reddy, Yong Lin, ...> ;Blood. 2021 Jan 21
• 17 citations
  Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or ...
  Talha Badar, Aniko Szabo, Shira Dinner, Michaela Liedtke, Madelyn Burkart, Rory M. Shallis, Ilana R. Yurkiewicz, Eric Kuo, Muhammad Ali Khan, Suresh Kumar Balasubraman...> ;Cancer. 2021 Apr 1
• 9 citations
  Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome.
  Liron Barnea Slonim, Juehua Gao, Madelyn Burkart, Oluwatobi E. Odetola, Masha Kocherginsky, Shira Dinner, Xinyan Lu, Firas Wehbe, Lawrence J. Jennings, Jessica K. Altm...> ;Leukemia. 2021 Jul 1
• 24 citations
  Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.
  Nicole A. Carreau, Orrin Pail, Philippe Armand, Reid W. Merryman, Ranjana H. Advani, Michael A. Spinner, Alex F. Herrera, Robert T. Chen, Sarah Tomassetti, Radhakrishn...> ;The Oncologist. 2020 Oct 1
• 6 citations
  Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma
  Reid W. Merryman, Nicole A. Carreau, Ranjana H. Advani, Michael A. Spinner, Alex F. Herrera, Robert T. Chen, Sarah Tomassetti, Radhakrishnan Ramchandren, Muhammad Hami...> ;The Oncologist. 2020 Jun 1
• 10 citations
  Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
  Talha Badar, Aniko Szabo, Martha Wadleigh, Michaela Liedtke, Shukaib Arslan, Caitlin Siebenaller, Ibrahim Aldoss, Elizabeth Schultz, Mehrdad Hefazi, Mark R. Litzow, Er...> ;Clinical Lymphoma, Myeloma & Leukemia. 2019 Nov 13
• 24 citations
  Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.
  Pallawi Torka, Shalin Kothari, Suchitra Sundaram, Shaoying Li, L. Jeffrey Medeiros, Emily C. Ayers, Daniel J. Landsburg, David A. Bond, Kami J. Maddocks, Anshu Giri, B...> ;Blood Advances. 2020 Jan 28
• 28 citations
  Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
  Talha Badar, Aniko Szabo, Anjali S. Advani, Martha Wadleigh, Shukaib Arslan, Muhammad Ali Khan, Ibrahim Aldoss, Caitlin Siebenaller, Elizabeth Schultz, Mehrdad Hefazi,...> ;Blood Advances. 2019 Nov 13
• 21 citations
  Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma.
  Madelyn Burkart, Michael Schieber, Sanjib Basu, Palmi Shah, Parameswaran Venugopal, Jeffrey A. Borgia, Leo I. Gordon, Reem Karmali> ;British Journal of Haematology. 2019 Apr 2
• 20 citations
  Future health of AYA survivors.
  Madelyn Burkart, Stacy D. Sanford, Shira Dinner, Lisa K. Sharp, Karen E. Kinahan> ;Pediatric Blood & Cancer. 2019 Feb 1
• Join now to see all

Abstracts/Posters

• Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
  Madelyn Burkart, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
  Madelyn Burkart, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Madelyn Burkart, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
  Madelyn Burkart, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
  Madelyn Burkart, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Madelyn Burkart, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
  Madelyn Burkart, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
  Madelyn Burkart, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
  Madelyn Burkart, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018